


PHARMACEUTICAL 2022

ATAI Life Sciences N.V. Rank 119 of 466









PHARMACEUTICAL 2022

ATAI Life Sciences N.V. Rank 119 of 466



The relative strengths and weaknesses of ATAI Life Sciences N.V. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ATAI Life Sciences N.V. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 49% points. The greatest weakness of ATAI Life Sciences N.V. is the variable Net Income, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 220%, being 142% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	375,082
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,935
Liabilities, Non-Current	4,097
Other Assets	38,935
Other Compr. Net Income	-7,695
Other Expenses	11,491
Other Liabilities	3,175
Other Net Income	-42,428
Other Revenues	20,376
Property and Equipment	149
Research and Development	47,956
Selling, General and Administrative Expense	92,745

Output Variable	Value in 1000 USD
Assets	414,166
Liabilities	28,207
Expenses	152,192
Revenues	20,376
Stockholders Equity	385,959
Net Income	-174,244
Comprehensive Net Income	-178,092
Economic Capital Ratio	220%

